文献速递淋巴瘤

卡非佐米、来那度胺、地塞米松(KRD)方案治疗BTK抑制剂复发或难治性套细胞淋巴瘤:意大利淋巴瘤基金会Ⅱ期研究

Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi.
PubMed 文献 · Br J Haematol · 2024-06-28

该Ⅱ期研究评估KRD方案治疗BTKi复发/难治或不耐受且需治疗的套细胞淋巴瘤患者,主要终点为12个月总生存率。2019年9月至2020年12月从11个意大利中心入组16例,中位随访2.37个月(95%CI 0.92-6.47),12个月OS为13%,ORR为19%,3-4级不良事件发生率为35%。因方案预设停止规则,入组提前终止,作者认为KRD在BTKi复发/难治的晚期套细胞淋巴瘤中疗效不满意且毒性过大。

要点

  • KRD方案治疗BTKi复发/难治套细胞淋巴瘤的12个月OS为13%,ORR为19%。
  • 3-4级不良事件发生率为35%,研究因预设停止规则提前终止入组。
  • 作者结论认为该方案在BTKi复发/难治晚期套细胞淋巴瘤中疗效不满意且毒性过大。

核心结论

  • KRD方案在BTKi复发/难治的晚期套细胞淋巴瘤患者中疗效不满意且毒性过大。
  • 上述结果导致研究按照方案预设停止规则提前终止入组。

研究设计与样本

  • 这是一项Ⅱ期试验,评估卡非佐米-来那度胺-地塞米松(KRD)联合方案在BTKi复发/难治或不耐受且需治疗的套细胞淋巴瘤患者中的疗效与安全性。
  • 主要目的是以12个月总生存(12个月OS)评价KRD联合方案的抗肿瘤疗效。
  • 2019年9月至2020年12月从11个意大利中心入组16例患者。

主要发现

  • 中位随访2.37个月(95%CI 0.92-6.47)时,12个月OS为13%。
  • 3-4级不良事件发生率为35%。
  • 总体缓解率(ORR)为19%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因方案预设停止规则提前终止入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is a rare lymphoproliferative neoplasm considered incurable, with a median survival of 3-5 years. In recent years, Bruton's tyrosine kinase inhibitors (BTKi) have been introduced, demonstrating high therapeutic activity. However, the prognosis for MCL patients failing ibrutinib therapy is particularly poor, with a survival expectation of a few months. In this phase II trial, we assessed the efficacy and safety of the carfilzomib-lenalidomide-dexamethasone (KRD) combination in MCL patients who were relapsed/refractory (R/R) or intolerant to BTKi and in need of treatment. The primary objective of the study was to evaluate the antitumor efficacy of the KRD combination in terms of 12-month overall survival (12-month OS). From September 2019 to December 2020, 16 patients were enrolled from 11 Italian centers. After a median follow-up of 2.37 months (95% CI 0.92-6.47), the 12-month OS was 13%. The rate of grade 3-4 adverse events (AEs) was 35%, and the overall response rate (ORR) was 19%. These results led to the premature termination of enrollment, as defined in the protocol stopping rules. The efficacy of the KRD combination in advanced-stage MCL patients who are R/R to BTKi is unsatisfactory and too toxic.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Cavallo F, Clerico M, Lucchini E, et al. Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi. Br J Haematol. 2024. PMID: 38938122. doi:10.1111/bjh.19617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。